Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.

As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.

Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.

ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.

Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.

Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.

The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.

David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.